Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
Số trang: 10
Loại file: pdf
Dung lượng: 478.94 KB
Lượt xem: 6
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011.
Nội dung trích xuất từ tài liệu:
Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
Nội dung trích xuất từ tài liệu:
Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Phase I study Topoisomerase-I inhibitor Maximum tolerated dose Dose-limiting toxicityTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 173 0 0 -
6 trang 168 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 144 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 121 0 0 -
12 trang 94 0 0
-
19 trang 75 0 0
-
17 trang 65 0 0
-
9 trang 45 0 0
-
12 trang 39 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0